泰杜格卢提德不良事件的现实世界分析:基于FAERS数据库的药监测研究
Xiaogan Wang1,2, Hao Chen1,2, Shuangshuang Han1,2
1First Clinical Medical College, Nanjing University of Chinese Medicine, Nanjing, China.
Frontiers in pharmacology
|September 27, 2024
概括
泰德古胺有助于短肠综合征 (SBS) 患者,但现实世界的不良药物事件 (AEs) 需要研究. 这项对FDA FAERS数据的分析发现了新的有害事物,如结石病,改善了临床监测.
科学领域:
- 药物监督 药物监督 药物监督
- 胃肠病学 胃肠病学
- 药品安全 药品安全
背景情况:
- 泰杜格卢提德是一种类似于葡萄糖的2类型,通过增强营养吸收来治疗短肠综合征 (SBS).
- 临床试验数据主要记录了teduglutide的不良药物事件 (AE).
- 关于teduglutide的安全性概况的现实世界数据有限.
研究的目的:
- 通过使用现实世界的数据来评估泰杜格胺的不良事件 (AE) 概况.
- 为了识别与泰杜格胺治疗相关的潜在的新安全信号.
主要方法:
- 从2013年第一季度到2023年第三季度的FDA不良事件报告系统 (FAERS) 数据的不成比例分析.
- 使用报告赔率比率 (ROR),比例报告比率 (PRR),BCPNN和EBGM算法.
- 确定了有关与特杜格卢提德相关的副作用的主要嫌疑人报告.
主要成果:
- 分析了来自1380多万个FAERS记录中的10,114份泰杜格卢提德嫌疑人报告.
- 在27个系统器官类别 (SOC) 中确定了260个主要不成比例的首选术语 (PT).
- 新发现的潜在副作用包括体重减轻,血管器官感染,脱水和石病.
结论:
- 这些发现证实了已知的teduglutide副作用,并突出了以前未报告的信号,如结石病.
- 这种现实世界的证据可以加强对特杜格卢的临床监测和风险管理.
- 该研究强调了药物监测在识别罕见或新出现的不良事件方面的重要性.
更多相关视频
00:04A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition
Published on: September 20, 2019
10.6K
08:44Preparation, Administration, and Assessment of In Vivo Tissue-Specific Cellular Uptake of Fluorescent Dye-Labeled Liposomes
Published on: July 30, 2020
4.3K
相关概念视频
Pharmacovigilance
786
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
786
Drug Regulation
1.3K
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
1.3K
Antiepileptic Drugs: Potassium Channel Activators
149
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
149
Clinical Trials: Overview
2.9K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
2.9K
Glucagon-like Receptor Agonists
305
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
305
Insulin: Dosing Regimen and Adverse Effects
156
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
156
